Abstract
Atrial fibrillation was first described electrocardiographically in 19091. Recently its important role as a cause of morbidity and mortality has become apparent. More than 3 million cases of atrial fibrillation are currently present in the United States2 and the number will increase further with the ageing of the population. The condition accounts for approximately 75 000 strokes per year in the United States3.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lewis T. Auricular fibrillation: a common clinical condition. Br Med J 1909; 2: 1528.
Waldo AL, Pratt CM. Acute treatment of atrial fibrillation and flutter-ibutilide in perspective. Am J Cardiol 1996; 78: 1–2.
Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–7.
Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988; 19: 937–41.
Michelucci A, Padeletti L, Fradella GA. Atrial refractoriness and spontaneous or induced atrial fibrillation. Acta Cardiol 1982; 5: 333–44.
Cosio FG, Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiologic studies in atrial fibrillation. Slow conduction of the background for reentry. Am J Cardiol 1983; 51: 122–30.
Henry WL, Morganroth J, Pearlman AS et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53: 273–9.
Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J 1994; 15: 9–16.
Schwartz PJ, Zara A. The Sicilian Gambit revisited theory and practice. Eur Heart J 1992; 13 (suppl. F): 23–9.
Bigger TJ Jr, Breithardt G, Brown AM et al. The Task Force of the working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831–51.
Spratt KA, Docherty JE. Digitalization: principles and practice of digitalis. In Messerli FH, editor. Cardiovascular Drug Therapy. Philadelphia, WB Saunders; 1996: 1136–46.
Wellens HJJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus movement tachycardia in patients with Wolf-Parkinson-White syndrome. Circulation 1973; 47: 1229–33.
Falk RH. Proarrhythmic responses to atrial anti-arrhythmic therapy. In Falk RH, Podrid PJ, editors. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press; 1992: 283–306.
Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503–6.
Kuppersmith J. Cellular mechanisms of antiarrhythmic action of beta blockers. In Deedwania PC, editor. Betablockers and Cardiac Arrhythmias. New York: Marcel Dekker; 1992: 1–30.
Anastasiou-Nana MI, Nanas JN, Menlove RL, Anderson JL. Experimental antifibrillatory effects of calcium channel blockade with diltiazem: comparison with 0-blockade and nitroglycerin. J Cardiovasc Pharmacol. 1984; 6: 780–7.
The Esmolol vs Placebo Multicenter Study Group: Anderson S, Blanski L, Byrd RC et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986; 111: 42–8.
The Esmolol vs placebo Multicenter Study Group: Abrams J, Allen J, Allin D et al. Efficacy and safety of esmolol vs propranolol in the treatment of supra-ventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 1985; 110: 913–22.
Singh BN, Control of cardiac arrhythmias by modulation of the slow myocardial channel. In Horowitz L, Partridge LD, Leach JK, editors. Calcium Channels, Their Properties, Functions, Regulation and Clinical Significance. Boca Raton, FL: CRC Press; 1991: 327–56.
Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multi-center study. J Am Coll Cardiol 1991; 18: 891–9.
Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316–24.
Borgeat A, Goy J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496–8.
Coplen SE, Antman E, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990; 82: 1106–16.
Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL on behalf of Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32.
Ogunkelu JB, Damato AN, Akhtar M et al. Electrophysiologic effects of procainamide in subtherapeutic to therapeutic doses in human atrioventricular conduction system. Am J Cardiol 1976; 37: 724–31.
Edvardsson N. Comparison of class I and class III action in atrial fibrillation. Eur Heart J 1993; 14 (suppl. H): 62–6.
Ladd AT. Procainamide induced lupus erythematosus. N Engl J Med 1962; 267: 1357–8.
Sharma AJ, Yee R, Graudon G, Klein GJ. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987; 10: 373–81.
Campbell TJ, Morgan JJ. Treatment of atrial arrhythmias after cardiac surgery with intravenous disopyramide. Aust NZJ Med 1980; 10: 644–9.
Stewart DE, Ikram H. The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. NZ Med J 1984; 97: 148–50.
Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomized trial. Br Heart J 1985; 54: 86–90.
Teichman SL, Fisher JD, Matos JA, Kim SG. Disopyramide-pyridostignine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 1985; 7: 108–13.
Wald RW, Waxman MB, Colman JM. Torsades de pointes ventricular tachycardia: a complication of diso- pyramide shared with quinidine. J Electrocardiol 1981; 14: 301–7.
Ikeda N, Singh BN, Davis LO, Hauswirth O. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 1985; 5: 303–10.
Wang Z, Page P, Nattel S. Mechanism of flecainide’s antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992; 71: 271–87.
Camm Ai, Katritsis D, Nuain SO. Effects of flecainide on atrial electrophysiology in Wolff-Parkinson-White syndrome. Am J Cardiol 1992; 70: 33–37A.
Donovan KD, Cobb DJ, Coombs LJ et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991; 67: 137–41.
Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in conversion of atrial fibrillation. Eur Heart J 1993; 14: 1127–31.
Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781–8.
Anastasiou-Nana MI, Anderson JL, Stewart JR et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable pro-arrhythmic effect. Am Heart J 1987; 113: 1071–7.
Kohlardt M, Seifert C. Inhibition of Vmax of the action potential by propafenone and its voltage-, time-and pH-dependence in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1980; 315: 55–62.
Capucci A, Villani GQ, on behalf of the SATE Group. Propafenone oral dose plus digitalis in converting atrial fibrillation to sinus rhythm: a placebo-controlled trial. Circulation 1995; 92: 1–775 (abstract).
Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063–71.
Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Amiodarone: application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984; 22: 229–35.
Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luchett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572–5.
Gosselink M, Crijins HJ, Van Gelder IC, Hilige H, Wiesfeld ACP, Lie KT. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. J Am Med Assoc 1992; 267: 3289–93.
Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19: 1054–9.
Anastasiou-Nana MI, Nanas JN, Nanas SN et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol 1994; 23: 253–8.
Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992; 70: 1023–7.
Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Pharmacokinetics of amiodarone after intravenous and oral administration. J Clin Pharmacol Ther Toxicol. 1982; 20: 524–9.
Nanas JN, Anastasiou-Nana MI, Margari ZJ, Karli J, Moulopoulos SD. Redistribution of amiodarone in heart transplant recipients treated with the drug before operation. J Heart Lung Transplant. 1997; 16: 387–9
Anastasiou-Nana MI, Anderson JL, Nanas JN et al. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias. Can J Cardiol. 1986; 2: 138–45.
Weinberg BA, Miles WM, Klein LS et al. Five year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109–20.
Singh BN. Electrophysiologic basis for the anti-arrhythmic actions of sotalol and comparison with other agents. Am J Cardiol 1993; 72: 8–18A.
Sung RJ, Tan HL, Karagounis L et al and the Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995; 129: 739–48.
Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with dgoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995; 76: 495–8.
Anastasiou-Nana MI, Anderson JL, Askins JC, Gilbert EM, Nanas JN, Menlove RL. Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. Am Heart J 1987; 114: 288–96.
Anastasiou-Nana MI, Gilbert EM, Miller RH et al. Usefulness of d,1 sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67: 511–16.
Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996; 78 (suppl. 8A): 12–16.
Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–21.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Anastasiou-Nana, M.I. (1998). Mechanisms of Drug Action in Atrial Fibrillation. In: Vardas, P.E. (eds) Cardiac Arrhythmias, Pacing & Electrophysiology. Developments in Cardiovascular Medicine, vol 201. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5254-9_4
Download citation
DOI: https://doi.org/10.1007/978-94-011-5254-9_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6210-7
Online ISBN: 978-94-011-5254-9
eBook Packages: Springer Book Archive